Literature DB >> 7678726

Physical stabilization of acidic fibroblast growth factor by polyanions.

D B Volkin1, P K Tsai, J M Dabora, J O Gress, C J Burke, R J Linhardt, C R Middaugh.   

Abstract

Acidic fibroblast growth factor (aFGF) is markedly stabilized by heparin. Partially due to the heterogeneity of heparin preparations, the nature of the aFGF polyanion binding site is still ill-defined. We have, therefore, investigated a wide variety of well-defined polyanions in terms of their ability to stabilize human recombinant aFGF (15-154) against thermal denaturation. The specificity of the interaction between aFGF and polyanions is shown to be remarkably weak with a surprising number of polyanions (including small phosphorylated and sulfated compounds as well as highly charged biopolymers) able to induce physical stability. Temperature-dependent fluorescence and circular dichroism measurements show that many of these polyanionic compounds stabilize aFGF to the same extent as heparin. The ability of these agents to protect the three free thiol groups of aFGF from copper-catalyzed oxidation was also explored and significant protection was observed. The extent and electrostatic requirements of the protein's polyanion binding site were probed by the use of a series of well-defined heparin fragments and differentially phosphorylated inositol compounds. A tetrasaccharide fragment of heparin is the smallest unit of heparin capable of stabilizing aFGF against thermal denaturation. Increasing phosphorylation of inositol compounds (up to six phosphate groups per molecule) enhances the thermal stability of aFGF. These results are discussed in the context of a model of human aFGF based on the X-ray crystal structure of the bovine protein and previous studies by others of the heparin binding site of both acidic and basic FGF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678726     DOI: 10.1006/abbi.1993.1005

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  24 in total

1.  An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1.

Authors:  Mohammad A Alsenaidy; Tingting Wang; Jae Hyun Kim; Sangeeta B Joshi; Jihun Lee; Michael Blaber; David B Volkin; C Russell Middaugh
Journal:  Protein Sci       Date:  2012-02-06       Impact factor: 6.725

Review 2.  High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.

Authors:  Rajoshi Chaudhuri; Yuan Cheng; C Russell Middaugh; David B Volkin
Journal:  AAPS J       Date:  2013-10-31       Impact factor: 4.009

Review 3.  Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery.

Authors:  Tobias Miller; Melissa C Goude; Todd C McDevitt; Johnna S Temenoff
Journal:  Acta Biomater       Date:  2013-10-09       Impact factor: 8.947

Review 4.  Degradative covalent reactions important to protein stability.

Authors:  D B Volkin; H Mach; C R Middaugh
Journal:  Mol Biotechnol       Date:  1997-10       Impact factor: 2.695

5.  Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution.

Authors:  B S Chang; R M Beauvais; T Arakawa; L O Narhi; A Dong; D I Aparisio; J F Carpenter
Journal:  Biophys J       Date:  1996-12       Impact factor: 4.033

Review 6.  Advanced protein formulations.

Authors:  Wei Wang
Journal:  Protein Sci       Date:  2015-05-01       Impact factor: 6.725

7.  Aggregation pathway of recombinant human keratinocyte growth factor and its stabilization.

Authors:  B L Chen; T Arakawa; C F Morris; W C Kenney; C M Wells; C G Pitt
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

8.  Formulation design of acidic fibroblast growth factor.

Authors:  P K Tsai; D B Volkin; J M Dabora; K C Thompson; M W Bruner; J O Gress; B Matuszewska; M Keogan; J V Bondi; C R Middaugh
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

Review 9.  Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants.

Authors:  G Neufeld; T Cohen; H Gitay-Goren; Z Poltorak; S Tessler; R Sharon; S Gengrinovitch; B Z Levi
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

10.  Increased protein stability of FGF1 can compensate for its reduced affinity for heparin.

Authors:  Malgorzata Zakrzewska; Antoni Wiedlocha; Anna Szlachcic; Daniel Krowarsch; Jacek Otlewski; Sjur Olsnes
Journal:  J Biol Chem       Date:  2009-07-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.